Enabling the Nervous System to Repair Itself

We create innovative treatments for nervous system damage due to injury or disease.

NervGen Pharma

NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company creating innovative treatments that enable the nervous system to repair itself following damage. NervGen’s lead drug candidate, NVG-291 is currently in a Phase 1 clinical trial. The company’s initial target indications are spinal cord injury, Alzheimer’s disease and multiple sclerosis.

Stay Connected

Subscribe to our mailing list to stay up to date

The Latest

News Release

November 17, 2022

NervGen reported the US Patent and Trade Office issued US Patent No. 11,497,812 B2 Compositions and Methods for Inhibiting the Activity of LAR Family Phosphatases to Case Western Reserve University.


October 24, 2022

NervGen Pharma featured in Health Europa article outlining how NervGen is exploring approaches to Alzheimer’s treatment culminating in its own novel method for treating nervous system damage using the revolutionary NVG-291 drug.


February 11, 2022

Interview with Paul Brennan, NervGen President & CEO (Interview at 29:22 in video)